🎉 Wishing our readers, advertisers and collaborators a purposeful and prosperous 2026. Thank you for being part of our journey as we continue to inform, inspire and build impact together in the year ahead. 🎉 🎉 Wishing our readers, advertisers and collaborators a purposeful and prosperous 2026. Thank you for being part of our journey as we continue to inform, inspire and build impact together in the year ahead. 🎉
Yuyu Pharma to distribute Novartis Korea's prescription medicines

Yuyu Pharma and Novartis Korea have entered into an agreement in which Yuyu will have exclusive distribution rights for ...

August 4, 2021 | Wednesday | News
FDA approves Medtronic's Artificial Intelligence Algorithms for Cardiac Monitoring

Medtronic, (headquartered in Dublin, Ireland), the global leader in medical technology, announced U.S. Food and Dru...

July 29, 2021 | Thursday | News
Menarini Asia-Pacific strengthens men's health portfolio in China

Menarini Asia-Pacific Holdings Pte. Ltd., part of the Menarini Group, the world's largest Italian biopharmaceutical comp...

July 22, 2021 | Thursday | News
China supports global polio endgame strategy with new vaccine

Sinovac Biotech, a leading provider of biopharmaceutical products in China, has received a drug registration approval fr...

July 19, 2021 | Monday | News
Frontier Biotechnologies launches two drug regimen for HIV

In conjunction with the IAS Conference on HIV Science, Germany's Frontier Biotechnologies has announced positive top-lin...

July 19, 2021 | Monday | News
Eisai launches bile acid transporter inhibitor Goofice in Thailand

Eisai's Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofic...

July 19, 2021 | Monday | News
Jardiance (empagliflozin) approved in Europe for the treatment of heart failure

The European Commission has granted marketing authorization for Jardiance®(empagliflozin) as a treatment for adults ...

July 6, 2021 | Tuesday | News
Scientists propose repurposing anti-malarial drug Mefloquine to fight COVID-19

Japanese scientists are scanning the possibility of using an anti-malarial drug called mefloquine....

July 2, 2021 | Friday | News
eTheRNA, VUB expand collaboration to engineer next-generation mRNA therapeutics

eTheRNA immunotherapies, a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and ...

June 23, 2021 | Wednesday | News
Vectura, Incannex to advance IHL-216A for treatment of traumatic brain injury

Vectura Group has signed an agreement with Australia-based Incannex Healthcare to provide pre-clinical development servi...

June 22, 2021 | Tuesday | News
RSF Bio enters worldwide license agreement with Sanofi for cardiovascular drug

Rancho Santa Fe Bio, Inc. (RSF Bio), a San Diego, California-based clinical-stage cardiovascular platform company, annou...

June 18, 2021 | Friday | News
Merck to commercialize Type 2 Diabetes drug in six growth markets

Merck has signed a collaboration agreement with Janssen Pharmaceuticals NV around the commercialization of INVOKANA...

May 4, 2021 | Tuesday | News
S. Korea's Peptron licenses global development of ADCs for cancer treatment

Peptron, Inc., a South Korea-based biotech company, and Qilu Pharmaceutical, a China-based pharmaceutical company f...

April 19, 2021 | Monday | News
BioVersys receives €20M in EU financing to support new antibiotics development

The European Investment Bank (EIB) and BioVersys AG, a clinical-stage pharmaceutical company developing treatments ...

April 14, 2021 | Wednesday | News
SK Biopharma seizures/epilepsy drug to launch in Europe

SK Biopharmaceuticals, Co., Ltd., a global innovative pharmaceutical company, announced that cenobamate received marketi...

April 5, 2021 | Monday | News
Australian oncology drug Paxalisib receives rights to develop and commercialize in China

Sydney-based Kazia Therapeutics Limited, an oncology-focused drug development company announced that it has entered into...

April 5, 2021 | Monday | News
Astellas launches XOSPATA (gilteritinib) in Singapore to treat adult Leukaemia patients

Astellas Pharma Inc. announced on March 31, 2021, that XOSPATA® (generic name: gilteritinib) is now available for pr...

March 31, 2021 | Wednesday | News
Eisai's Anti Cancer agent Lenvatinib-Pembrolizumab combo receives EMA in Japan

Eisai Co., Ltd. announced on March 30, 2021 that the European Medicines Agency (EMA) has confirmed it has acce...

March 30, 2021 | Tuesday | News